Every GLP-1 Medication, Explained | The Plus SideZ

GLP-1 medications

Every GLP-1, explained simply

Every GLP-1 medication, from the first one approved to the newest options still in development. What each one is approved for, how it is taken, how it works, and what the clinical trials have found so far. Everything here reflects United States approvals from the FDA, so labels and availability differ if you are outside the US.

Which of these fits you, if any, depends on your health history, your insurance, and your prescriber's judgment. Trial percentages are averages from different trials with different lengths and populations, so treat them as a rough map, not a ranking. Bring this page to your appointment if it helps the conversation. Do not use it in place of one.

Last reviewed September 2026. This field moves quickly, and we update the page as labels change.

Available now in the US

Approved by the FDA and available by prescription in the United States.

{{ shownCount }}

No medication matches that. Try clearing the search or choosing All medications.
{{ m.tag }}

{{ m.brand }}

{{ m.sub }}

{{ m.taken }}

Approved for

  • {{ ind }}
    •

How it works. {{ m.works }}

What they found in the studies. {{ m.trials }}

The pipeline

What is in trials right now

The next wave is not only GLP-1. Much of it pairs GLP-1 with amylin, a separate appetite hormone, or drops GLP-1 altogether. Phases run 1 through 3, with 3 being the large trials that come before a filing. Several are also being studied beyond obesity, including for sleep apnea, liver disease, osteoarthritis and addiction. Nothing on this list can be prescribed for weight management in the United States yet, and drugs do fail at every stage.

Phase Candidate Company Being studied for Notes
{{ row.phase }}

{{ row.name }}
{{ row.generic }}

{{ row.company }}

{{ row.studiedFor }}
{{ row.how }}

{{ row.note }}

Trial phases and sponsors change frequently. For the current status of any specific study, ClinicalTrials.gov is the primary record.

No longer made

Byetta and Bydureon (exenatide, AstraZeneca) were among the earliest GLP-1 medications, approved for type 2 diabetes. Both have been discontinued by the manufacturer and are no longer available.

Hear it discussed

The specialists, in their own words

A label tells you what a medication is approved for. It does not tell you what the first month feels like, what to do when the scale stops moving, or how to appeal a denial. That is what the podcast is for.

Browse all episodes Join the community

Sources

  1. {{ src }}
    2.

Medication brand names on this page are the trademarks of their respective owners. Ozempic, Wegovy, Rybelsus, Saxenda and Victoza are trademarks of Novo Nordisk. Mounjaro, Zepbound, Trulicity and Foundayo are trademarks of Eli Lilly. We name them to identify the medications we are discussing, and we are not affiliated with, sponsored by, or endorsed by any manufacturer. No manufacturer pays us or has any say over this page.

Trial figures are averages across study populations of differing length and design. They are not a promise or prediction of what any individual will experience.

Approvals, indications and availability on this page are for the United States. Other countries have their own regulators, and a medication approved here may be unavailable, differently branded, or approved for different uses elsewhere. This page is general education, is not medical advice, and does not create a clinician-patient relationship. Talk with your own practitioner, and call 911 in an emergency.